← Back to Search

Other

CT-868 for Type 1 Diabetes

Phase 1
Recruiting
Research Sponsored by Carmot Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Female or male adults with Type 1 diabetes
BMI 25.0 - 35.0
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0 - 300 minutes
Awards & highlights

Study Summary

This trial will look into how a new drug affects people with Type 1 Diabetes to regulate their blood sugar.

Who is the study for?
Adults aged 18-65 with Type 1 diabetes, a BMI between 25.0 and 35.0, who have been managing their condition with an insulin pump or multiple daily injections for at least three months are eligible. Those with a history of cancer, significant medical conditions, surgical weight loss treatments, or uncontrolled diabetes cannot participate.Check my eligibility
What is being tested?
The trial is testing the effects of CT-868 on blood sugar control in people with Type 1 Diabetes compared to a placebo and Victoza (a known diabetes medication). Participants will be randomly assigned to receive one of these treatments.See study design
What are the potential side effects?
Possible side effects may include reactions at the injection site, low blood sugar levels (hypoglycemia), nausea, vomiting, diarrhea and potential allergic reactions to the medications used.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
Adults with Type 1 diabetes, whether male or female.
Select...
Your body mass index (BMI) is between 25 and 35.
Select...
You have been using an insulin pump or giving yourself multiple daily injections for at least 3 months.
Select...
You have had type 1 diabetes for at least 3 years.
Select...
You are between 18 and 65 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0 - 300 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and 0 - 300 minutes for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To assess area under the curve (AUC) in glucose metabolism during MMTT
Secondary outcome measures
Area under the acetaminophen concentration-time (AUC)
To assess changes in continuous glucose monitoring (CGM) measures

Side effects data

From 2014 Phase 4 trial • 368 Patients • NCT02008682
15%
Nausea
11%
Decreased appetite
8%
Diarrhoea
6%
Lipase increased
1%
Sudden hearing loss
1%
Bronchitis
1%
Diabetic ketoacidosis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Liraglutide
Sitagliptin

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: CT-868Experimental Treatment1 Intervention
SC injection of CT-868 Intervention
Group II: VictozaActive Control1 Intervention
SC injection of active comparator
Group III: PlaceboPlacebo Group1 Intervention
SC injection of placebo matching CT-868 dose

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Carmot Therapeutics, Inc.Lead Sponsor
5 Previous Clinical Trials
438 Total Patients Enrolled
Michael ElliottStudy DirectorCarmot Therapeutics, Inc.
5 Previous Clinical Trials
438 Total Patients Enrolled

Media Library

CT-868 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05794581 — Phase 1
Type 1 Diabetes Research Study Groups: Victoza, CT-868, Placebo
Type 1 Diabetes Clinical Trial 2023: CT-868 Highlights & Side Effects. Trial Name: NCT05794581 — Phase 1
CT-868 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05794581 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this experiment seeking out participants that are more than 35 years of age?

"The age requirements for this research experiment necessitate that participants be at least 18 years old and not exceed 65."

Answered by AI

What are the eligibility requirements to join this research program?

"To be accepted for this trial, participants must have type 1 diabetes and fall between 18-65 years old. Currently, 24 individuals are sought after to fill the study participation slots."

Answered by AI

Is there a potential risk posed by CT-868 to the general public?

"Taking into account the limited amount of evidence available, our team at Power gave CT-868 a score of 1 on the safety scale. This is because it's currently undergoing Phase One trials where both efficacy and safety are being experimentally tested."

Answered by AI

What is the current number of individuals participating in this clinical experiment?

"Affirmative. According to information provided on clinicaltrials.gov, this trial is actively in search of suitable candidates as it was initially posted on March 1st 2023 and edited most recently on the 30th of that same month. A total 24 patients are needed across a single medical centre."

Answered by AI

Could you tell me if this experiment is currently recruiting participants?

"Per the information on clinicaltrials.gov, this study is currently in search of participants. It was first made public on March 1st 2023 and last edited 30 days later."

Answered by AI
~12 spots leftby Mar 2025